Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO and Chairman of the Board of Directors & Founder Bertrand de Poly as Chief Strategy & Technology Officer
3.5.2023 20:04:00 EEST | Business Wire | Press release
Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors. Founder Bertrand de Poly will assume the role of Chief Strategy & Technology Officer, focusing on strategy and technological development, along with his continued service on the board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230503005760/en/
F. Samuel Eberts III, Chief Executive Officer and Chairman of the Board of Directors (Photo: Business Wire)
This evolution in management aims to take the company to its next stage of growth, building on recent achievements including the acceptance of a clinical study manuscript with Johnson & Johnson at Boston University and Fox Chase Cancer Center, to be presented at the American Thoracic Society meeting in Washington, DC on May 19-24, 2023.
Samuel Eberts brings to Aquyre Biosciences decades of experience at the intersection of healthcare, law, and academia. His varied career includes equity partnership and board, and investment committee membership at a private equity firm whose collaboration with Harvard-affiliated Mass General’s Wellman Center facilitated world-class medical insights, and ongoing engagements as a Partner at Market Street HealthCare Partners, a private equity sponsor for healthcare investments. For 15 years, Sam was part of the senior management team at LabCorp, where he served as Chief Legal Officer, Corporate Secretary, and Senior Vice President of Corporate Affairs, with oversight of regulatory, government relations, and merger and acquisition activities. He is a senior advisor for healthcare investments to Aquyre’s shareholder, Invescore. Sam is also a Senior Lecturing Fellow at Duke University School of Law, a member of the advisory board for the Wilson Center, and has served on the World Policy Institute Advisory Board, the Harvard Law School Corporate Governance Forum, and the John F. Kennedy School of Government Healthcare Policy Leadership Council. He also serves on the board of several non-profit organizations.
“I am delighted that Samuel has agreed to help take Aquyre to the next level of its growth journey as we further refine our technology and scale our partner solutions and corporate operations. I look forward to working with him to help ensure the success of our company,” said Bertrand de Poly.
“I am particularly pleased that among the many shareholders of Aquyre, Canon Medical Systems Corporation, the medical equipment subsidiary of the optical, imaging, and industrial multinational Canon, Inc., is a strategic investor,” said Samuel Eberts. “I am honored to be leading such an impressive collection of people and products and am excited about the potential of Aquyre Biosciences. It is humbling and exciting to be part of an organization that will play an important role in healthcare. We are well positioned to bring a new level of precision in diagnosis of cancer, improving the lives of patients.”
About Aquyre Biosciences
Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in two-minute lung biopsy adequacy assessment. Powered by two proprietary technologies including Dynamic Cell Imaging™ (DCI), CelTivity can scan a biopsy and measure intracellular and metabolic activity throughout extracted tissue. This activity is presented in a heatmap, making it easy to interpret. The assessment does not require any cutting or staining, meaning the same tissue assessed for adequacy can go to final pathology to review for cancer, granuloma, lymphocytes, and more. Aquyre Biosciences is headquartered out of Weston, Mass. For more information, please visit www.aquyre.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005760/en/
Contact information
Emily Ritacco
Director of Marketing
eritacco@aquyre.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sugar Taxes Under Scrutiny: New Competere Study Questions Health Outcomes and Warns of Unintended Consequences5.11.2026 13:00:00 EET | Press release
As governments debate sugar taxation and nutrition measures, a new policy paper asks a critical question: Do these interventions deliver lasting health improvements, for whom, and at what cost? Published by Competere with the support of the Association of Latin American Sugar Producers (UNALA), Understanding Sugar Beyond the Narrative – by Pietro Paganini – offers policymakers, journalists, and consumers an accessible guide to sugar’s role in health, sustainability, and the global economy. Combining scientific evidence with economic and policy analysis, the paper challenges common misconceptions and examines whether taxation, warning labels, and reformulation deliver measurable health benefits. While sugar taxes can influence prices, purchases, and product composition, evidence of lasting improvements in obesity, diabetes, and cardiovascular health remains limited. Intermediate outcomes should not be confused with demonstrated health benefits. Reviewed studies estimate reductions of 2.
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates5.11.2026 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization.” (Amounts in thousands of U.S. dollars and unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 % Change 2026 2025 % Change Net product revenues $ 1,855,057 $ 1,395,013 33 % $ 5,022,180 $
Klarna Goes Global With Anti-Scam Call Verification5.11.2026 12:52:00 EET | Press release
Klarna, the everyday finance network, today announced its popular in-app Call Status Detection tool is now live globally, giving consumers a reliable and simple way to check whether someone calling them is genuinely from Klarna. Call Status Detection has already helped thousands of consumers verify calls since it launched in the Nordics in September. The feature has now been rolled out globally, reflecting Klarna’s commitment to protecting its customers from fraud. Call Status Detection is quick and easy to use by design. If a customer takes a call from someone claiming to be Klarna, all they have to do is open the Klarna app and check the banner at the top of their screen — green means the call is verified and it is safe to continue, while amber means Klarna cannot verify the call and the customer should hang up. The feature builds on Klarna’s existing anti-fraud measures like the Klarna Inbox, which enables verification of written communication like emails, texts and letters, and aim
Prodalim Acquires South Africa’s Brenn-O-Kem, Expanding Its Global Circular Economy Platform with High-Value Grape-Based Specialty Ingredients5.11.2026 12:17:00 EET | Press release
Prodalim announced the acquisition of Brenn-O-Kem (BOK), a South African leader in upcycling winery by-products into high-value specialty ingredients for the wine, food and beverage, nutraceutical, agricultural and pharmaceutical industries. The acquisition strengthens Prodalim’s global circular economy platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103526127/en/ BOK transforms grape pomace and wine lees into a broad portfolio of natural, clean-label ingredients, including recycled aromatic alcohol for the wine and spirits industry; tartaric acid and derivatives for food, beverage and pharmaceutical applications; grape seed extracts for nutraceuticals; grape skin extracts for natural colors; grape seed oils and wine concentrates for culinary applications; and recycled compost for animal nutrition. Prodalim will acquire 93.25% of BOK for 37M USD. Founded in 1968, BOK operates three production sites in South Afric
SES Delivers Solid 9 Months & Q3 2026 Results and Reiterates Full-Year Outlook5.11.2026 11:22:00 EET | Press release
SES S.A. announces financial results for the nine and three months ended September 30, 2026. YTD 2026 Performance (€ million) YTD 2026 as reported (1) YTD 2025 as reported (1)(5) ∆ At constant FX (2) YTD 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.16 1.11 1.11 Revenue 2,472 1,743 +45.5% 2,628 -2.0% Adjusted EBITDA (4) 1,138 838 +40.0% 1,170 +1.4% 1) ‘Reported basis’ with Intelsat fully consolidated from July 17, 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralize currency variations 3) ‘Like-for-like basis’ is as if Intelsat was fully consolidated from January 1, 2024 4) Excluding operating expenses/income recognized in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) 5) 2025 has been restated to reflect Purchase Price Allocation (PPA) adjustments recorded in connection with the acquisitio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom